Anticholinergic therapy for airway diseases

David B. Jacoby; Allison D. Fryer

doi:10.1016/S0024-3205(01)01053-0

Anticholinergic therapy for airway diseases

David B. Jacoby, Allison D. Fryer

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

Original language	English (US)
Pages (from-to)	2565-2572
Number of pages	8
Journal	Life Sciences
Volume	68
Issue number	22-23
DOIs	https://doi.org/10.1016/S0024-3205(01)01053-0
State	Published - Apr 27 2001
Externally published	Yes

Keywords

Asthma
COPD
Ipratropium
Rhinitis
Tiotropium

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/S0024-3205(01)01053-0

Cite this

@article{bedd23f73bc74a11bf9eae6815829ac0,

title = "Anticholinergic therapy for airway diseases",

abstract = "Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.",

keywords = "Asthma, COPD, Ipratropium, Rhinitis, Tiotropium",

author = "Jacoby, {David B.} and Fryer, {Allison D.}",

year = "2001",

month = apr,

day = "27",

doi = "10.1016/S0024-3205(01)01053-0",

language = "English (US)",

volume = "68",

pages = "2565--2572",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "22-23",

}

TY - JOUR

T1 - Anticholinergic therapy for airway diseases

AU - Jacoby, David B.

AU - Fryer, Allison D.

PY - 2001/4/27

Y1 - 2001/4/27

N2 - Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

AB - Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over β-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

KW - Asthma

KW - COPD

KW - Ipratropium

KW - Rhinitis

KW - Tiotropium

UR - http://www.scopus.com/inward/record.url?scp=0035957576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035957576&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(01)01053-0

DO - 10.1016/S0024-3205(01)01053-0

M3 - Article

C2 - 11392627

AN - SCOPUS:0035957576

SN - 0024-3205

VL - 68

SP - 2565

EP - 2572

JO - Life Sciences

JF - Life Sciences

IS - 22-23

ER -

Anticholinergic therapy for airway diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this